ArticleBlood cell therapy2026
Real-World Outcomes of Allogeneic Stem Cell Transplantation in Relapsed Hodgkin Lymphoma: A Single-Center Experience from India.
Article in Blood cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Relapsed Hodgkin lymphoma (HL) after autologous stem cell transplantation (auto-HSCT) remains a major therapeutic challenge with few curative options. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may provide durable disease control, yet outcome data from tertiary-care centres in India are limited. Objective: To evaluate real-world outcomes of allo-HSCT in patients with chemotherapy-sensitive relapsed HL at a tertiary care centre in North India. Methods: This retrospective study included patients with chemotherapy-sensitive relapsed HL who underwent allo-HSCT at the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, between January 2017 and December 2023. Clinical data including baseline characteristics, transplant parameters, complications, and survival outcomes were reviewed. Descriptive statistics were used, and overall survival (OS) was estimated using the Kaplan-Meier method. Results: Five patients (median age 18 years; range 14-30) with chemotherapy-sensitive relapse following auto-HSCT underwent allogeneic transplantation in complete remission (CR) after salvage therapy. Donors included haploidentical (n=3), matched unrelated (n=1), and matched sibling (n=1). Four patients received reduced-intensity conditioning; one received myeloablative conditioning. Graft-versus-host disease (GVHD) prophylaxis included post-transplant cyclophosphamide (PT-Cy) in four patients. Neutrophil and platelet engraftment occurred at median 15 and 16 days, respectively. All patients developed bacterial infections; one succumbed to Gram-negative sepsis. Acute grade III GVHD occurred in one patient, and two developed limited chronic GVHD. At a median follow-up of 44 months, four patients remained in continuous remission, with a 3-year OS of 80%. Conclusion: In Indian patients with chemotherapy-sensitive relapsed HL, allo-HSCT using reduced-intensity and reduced toxicity conditioning regimens and post-transplant cyclophosphamide-based regimens has proven feasible and effective, yielding encouraging survival outcomes within routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.